VenatoRx Pharmaceuticals Awarded NIAID R01 Grant to Uncover Determinants of Gram-Negative Permeability
MALVERN, PA — VenatoRx Pharmaceuticals, Inc., a world leader in antibacterial and antiviral drug research and development, announced that it has received $1.9 million in first-year funding from the National …
Read More